(Colorectal Cancer) Tecentriq + Cobimetinib Combination Therapy Failed to Extend Overall Survival in Previously Treated Locally Advanced or Metastatic Colorectal Cancer Patients
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
- May 22, 2019
- Read time: 1 minute
Tecentriq + Cobimetinib Combination Therapy Failed to Extend Overall Survival in Previously Treated Locally Advanced or Metastatic Colorectal Cancer Patients
On April 16, 2019, The Lancet published comparative Phase 3 clinical trial efficacy results for previously treated locally advanced or metastatic colorectal cancer patients using Tecentriq (atezolizumab) + cobimetinib combination therapy, Tecentriq monotherapy, and regorafenib monotherapy.
This trial enrolled patients who had received at least two prior lines of treatment. The primary endpoint was overall survival, and secondary endpoints were progression-free survival, objective response rate, and duration of response. The most commonly occurring adverse events from this combination therapy and their rates were: diarrhea 11%, anemia 6%, elevated creatine phosphokinase 7%, and fatigue 4%.
Based on the trial results, both the combination therapy and Tecentriq monotherapy did not show significant improvement in overall survival compared to regorafenib monotherapy.
Source: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30027-0/fulltext
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5